*** TEST ***
Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Mesoangioblasts at 20: from the embryonic aorta to the patient bed

[thumbnail of Publisher's version]
Preview
PDF (Publisher's version) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB

Item Type:Review
Title:Mesoangioblasts at 20: from the embryonic aorta to the patient bed
Creators Name:Cossu, G., Tonlorenzi, R., Brunelli, S., Sampaolesi, M., Messina, G., Azzoni, E., Benedetti, S., Biressi, S., Bonfanti, C., Bragg, L., Camps, J., Cappellari, O., Cassano, M., Ciceri, F., Coletta, M., Covarello, D., Crippa, S., Cusella-De Angelis, M.G., De Angelis, L., Dellavalle, A., Diaz-Manera, J., Galli, D., Galli, F., Gargioli, C., Gerli, M.F.M., Giacomazzi, G., Galvez, B.G., Hoshiya, H., Guttinger, M., Innocenzi, A., Minasi, M.G., Perani, L., Previtali, S.C., Quattrocelli, M., Ragazzi, M., Roostalu, U., Rossi, G., Scardigli, R., Sirabella, D., Tedesco, F.S., Torrente, Y. and Ugarte, G.
Abstract:In 2002 we published an article describing a population of vessel-associated progenitors that we termed mesoangioblasts (MABs). During the past decade evidence had accumulated that during muscle development and regeneration things may be more complex than a simple sequence of binary choices (e.g., dorsal vs. ventral somite). LacZ expressing fibroblasts could fuse with unlabelled myoblasts but not among themselves or with other cell types. Bone marrow derived, circulating progenitors were able to participate in muscle regeneration, though in very small percentage. Searching for the embryonic origin of these progenitors, we identified them as originating at least in part from the embryonic aorta and, at later stages, from the microvasculature of skeletal muscle. While continuing to investigate origin and fate of MABs, the fact that they could be expanded in vitro (also from human muscle) and cross the vessel wall, suggested a protocol for the cell therapy of muscular dystrophies. We tested this protocol in mice and dogs before proceeding to the first clinical trial on Duchenne Muscular Dystrophy patients that showed safety but minimal efficacy. In the last years, we have worked to overcome the problem of low engraftment and tried to understand their role as auxiliary myogenic progenitors during development and regeneration.
Keywords:Mesoderm, Myogenic Stem Cells, Pericyte, Muscular Dystrophy, Muscle Development
Source:Frontiers in Genetics
ISSN:1664-8021
Publisher:Frontiers Media SA
Volume:13
Page Range:1056114
Date:4 January 2023
Official Publication:https://doi.org/10.3389/fgene.2022.1056114
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library